PDL Biopharma (PDLI) Receives Media Sentiment Rating of 0.14

News articles about PDL Biopharma (NASDAQ:PDLI) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PDL Biopharma earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.0260834987609 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several equities research analysts have weighed in on the company. TheStreet raised PDL Biopharma from a “d+” rating to a “c-” rating in a report on Friday, March 9th. BidaskClub downgraded PDL Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, April 14th. Finally, Zacks Investment Research raised PDL Biopharma from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. PDL Biopharma currently has a consensus rating of “Hold” and a consensus price target of $3.50.

Shares of PDL Biopharma traded up $0.09, reaching $2.85, on Tuesday, Marketbeat reports. 95,044 shares of the stock were exchanged, compared to its average volume of 1,395,776. The company has a quick ratio of 9.75, a current ratio of 10.03 and a debt-to-equity ratio of 0.14. PDL Biopharma has a twelve month low of $2.15 and a twelve month high of $3.55. The company has a market capitalization of $417.27 million, a price-to-earnings ratio of 4.52 and a beta of 0.36.

PDL Biopharma (NASDAQ:PDLI) last released its earnings results on Thursday, March 8th. The biotechnology company reported $0.17 EPS for the quarter. PDL Biopharma had a return on equity of 11.76% and a net margin of 33.57%. The firm had revenue of $68.04 million during the quarter. research analysts anticipate that PDL Biopharma will post 0.12 EPS for the current fiscal year.

PDL Biopharma Company Profile

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Insider Buying and Selling by Quarter for PDL Biopharma (NASDAQ:PDLI)

Receive News & Ratings for PDL Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply